Clinical Trials in Baltimore

Showing 1701-1720 of 20,142 trials

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

NCT06525259

The goal of the DISCOVERY study is to provide innovative critical information regarding the unique natural history of glycemic control, insulin sensitivity, and β-cell function, and their mechanistic determinates, in obese adolescents at risk for developing type 2 diabetes.

Diabetes Mellitus Type 2, Childhood-Onset

George Washington University3,600 participantsStarted Oct 2024

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +17 more locations

Active Not RecruitingPhase 2< 1 mile

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

NCT02890355

This randomized phase II trial studies how well modified irinotecan hydrochloride, leucovorin calcium, fluorouracil (FOLFIRI) and veliparib as a second line of therapy work compared to FOLFIRI in treating patients with pancreatic cancer that has come back after a period of improvement (metastatic). Drugs used in chemotherapy, such as irinotecan hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether modified FOLFIRI and veliparib as second line therapy is more effective than FOLFIRI alone in treating metastatic pancreatic cancer.

Metastatic Pancreatic AdenocarcinomaRecurrent Pancreatic CarcinomaStage IV Pancreatic Cancer AJCC v6 and v7

National Cancer Institute (NCI)123 participantsStarted Sep 2016

Mobile, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +780 more locations

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Find Trials by Condition in Baltimore

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Medtronic Terminate AF Study

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants

Phase II Trial of Lung Chemoemobolization